The availability of generic Entresto in the USA is contingent on patent expirations and regulatory approvals. The primary active ingredients in Entresto are sacubitril and valsartan.
When Do Entresto's Key Patents Expire?
Novartis's Entresto (sacubitril/valsartan) is protected by several patents. One key patent related to the method of treating heart failure with the combination drug is expected to expire in 2025 [1]. However, the actual market exclusivity for a drug can extend beyond these primary patent dates due to various factors, including patent extensions and potential litigation [2]. Information on specific patent expiry dates and their implications can be found on resources like DrugPatentWatch.com [1].
What Happens After Patent Expiration?
Once the relevant patents expire and regulatory hurdles are cleared, generic versions of Entresto can be manufactured and marketed. This typically involves the U.S. Food and Drug Administration (FDA) approving Abbreviated New Drug Applications (ANDAs) for generic manufacturers. The ANDA process allows for the approval of a generic drug if it is demonstrated to be bioequivalent to the reference listed drug, in this case, Entresto.
Can Generic Entresto Be Available Before Patent Expiry?
In some cases, generic companies may challenge existing patents, leading to earlier generic entry if the challenge is successful. Conversely, patent holders may pursue legal actions to defend their patents and prevent generic competition. These legal battles can significantly impact the timeline for generic availability.
How Will Generic Entresto Affect Pricing?
The introduction of generic competition is generally expected to lead to a decrease in the price of Entresto. This is a common outcome in the pharmaceutical market when multiple manufacturers offer the same drug, increasing supply and competition. Patients and healthcare systems often see significant cost savings once generic options become available.